Can DHCR7 and GC variants lower vitamin D status?

Genetic variation plays a profound role in modulating systemic vitamin D status, independent of dietary intake and sun exposure.

Clinical evidence

• Large-scale genome-wide association studies (GWAS), such as those conducted by the SUNLIGHT Consortium, have established that common genetic variants in the DHCR7 and GC loci are robustly associated with circulating 25-hydroxyvitamin D [25(OH)D] levels.
• Carrying risk alleles at these loci—specifically the G allele of the DHCR7 variant rs12785878 and the minor allele of the GC variant rs2282679—is consistently linked to lower total serum 25(OH)D and an increased susceptibility to clinical vitamin D deficiency.

Mechanistic pathways

• Cutaneous Synthesis (DHCR7): The DHCR7 gene encodes 7-dehydrocholesterol reductase, a 54-kDa microsomal enzyme that converts 7-dehydrocholesterol (7-DHC) to cholesterol. The rs12785878 variant acts as a metabolic gateway; variants that increase this pathway's efficiency shunt the shared precursor 7-DHC toward cholesterol synthesis, depleting the dermal substrate pool available for ultraviolet B (UVB)-driven conversion into pre-vitamin D3.
• Systemic Transport (GC): The GC gene encodes vitamin D-binding protein (DBP), which binds and transports 80% to 90% of circulating 25(OH)D. The rs2282679 variant directly influences GC gene expression. The risk allele reduces circulating concentrations of DBP, limiting the total systemic transport capacity and directly resulting in lower measurable levels of total serum 25(OH)D.

Bottom line

• Bottom line: Genetic variations in DHCR7 and GC impair vitamin D status through distinct, highly established mechanisms—by reducing the availability of the synthesis precursor 7-DHC in the skin and lowering the concentration of the primary transport protein in circulation.